HCV genotype 4, 5 and 6: Distribution of viral subtypes and sustained virologic response rates in clinical trials of approved direct-acting antiviral regimens

2018 ◽  
Vol 25 (8) ◽  
pp. 969-975 ◽  
Author(s):  
S. D. Boyd ◽  
P. Harrington ◽  
T. E. Komatsu ◽  
L. K. Naeger ◽  
K. Chan-Tack ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Sustained Virologic Response ◽  
Response Rates ◽  
Virologic Response ◽  
Genotype 4 ◽  
Hcv Genotype ◽  
Direct Acting Antiviral ◽  
Direct Acting ◽  
Viral Subtypes

scholarly journals Incidence and Impact of Persistent Viremia on SVR Rates in Patients Receiving Direct-Acting Antiviral Therapy

2020 ◽  
Vol 7 (12) ◽  
Author(s):  
Alicia B Carver ◽  
Autumn D Zuckerman ◽  
Joshua DeClercq ◽  
Leena Choi ◽  
Cody A Chastain
Keyword(s):  
Antiviral Therapy ◽  
Real World ◽  
Sustained Virologic Response ◽  
Response Rates ◽  
Virologic Response ◽  
Direct Acting Antiviral ◽  
Rapid Virologic Response ◽  
Persistent Viremia ◽  
Direct Acting ◽  
High Sustained Virologic Response

Abstract Rates of persistent viremia (PV) while on direct-acting antiviral therapy were low (5.7%) in a real-world cohort of 983 patients. High sustained virologic response rates were achieved both in patients with PV (92.9%) and those with rapid virologic response (96.5%), without significant differences.

DI-062 Sustained virologic response rates of new direct acting antiviral agents for HCV

2016 ◽  
Vol 23 (Suppl 1) ◽  
pp. A145.2-A146
Author(s):  
C Caballero Requejo ◽  
M Onteniente Candela ◽  
JJ Franco Miguel ◽  
M Garcia Coronel ◽  
A Trujillano Ruiz ◽  
...  
Keyword(s):  
Sustained Virologic Response ◽  
Antiviral Agents ◽  
Response Rates ◽  
Virologic Response ◽  
Direct Acting Antiviral ◽  
Direct Acting ◽  
Direct Acting Antiviral Agents

Sustained virologic response and changes in liver fibrosis parameters following 12-wk administration of generic sofosbuvir and daclatasvir in HIV/HCV-coinfected patients with HCV genotype 4 infection

2020 ◽  
Vol 114 (4) ◽  
pp. 232-240
Author(s):  
Ahmed Cordie ◽  
Aisha Elsharkawy ◽  
Shereen Abdel Alem ◽  
Safa Meshaal ◽  
Wafaa El Akel ◽  
...  
Keyword(s):  
Antiviral Agents ◽  
Liver Stiffness ◽  
Virologic Response ◽  
Genotype 4 ◽  
Significant Fibrosis ◽  
Hcv Genotype ◽  
Direct Acting Antiviral ◽  
Significant Difference ◽  
Baseline Variable ◽  
Direct Acting

Abstract Background Novel direct-acting antiviral agents have shown great efficacy and tolerability in HCV-monoinfected patients. However, data are lacking regarding their efficacy and safety in HIV/HCV-genotype (GT) 4-coinfected patients. Methods A single-centre, prospective study including HIV/HCV-GT 4-coinfected patients who were treated with sofosbuvir and daclatasvir (SOF/DCV) was conducted for 12 wk. Sustained virological response (SVR) at week 12 post-treatment (SVR12), adverse events (AEs) and changes in liver stiffness measurement (LSM) at SVR12 in comparison with baseline were evaluated. Results SVR12 was achieved in 46 of 50 patients (92%). No significant difference in SVR12 was noticed among patients who received antiretroviral therapy (ART) regimens compared with those who did not receive ART regimens or between those with insignificant fibrosis (<F2) and those with significant fibrosis (≥F2) (p=0.9 and p=0.3, respectively). AEs occurred in 45 (90%) patients. The most frequent AEs were fatigue, headache and nausea. No treatment-related serious AEs or deaths were reported. HIV control was not compromised. LSM, fibrosis 4 score and aspartate aminotransferase-to-platelet ratio index showed a significant decrease at SVR12 when compared with baseline (p=0.0004, p=0.0003 and p<0.0001, respectively). Logistic regression analysis showed no association between baseline variables and SVR12 while significant fibrosis (≥F2) was the only baseline variable that was significantly associated with improvement of LSM at SVR12. Conclusion SOF/DCV achieved a high SVR12 and was well-tolerated in HIV/HCV-GT 4-coinfected patients.

Mo1385 - Favorable Sustained Virologic Response Rates Using Direct-Acting Antiviral Therapies at a Large Safety Net Hospital

2018 ◽  
Vol 154 (6) ◽  
pp. S-1189-S-1190
Author(s):  
Andrew Bryant ◽  
Avash Kalra ◽  
Angela Keniston ◽  
Aimee Truesdale ◽  
Alvaro Martinez-Camacho
Keyword(s):  
Sustained Virologic Response ◽  
Response Rates ◽  
Safety Net ◽  
Virologic Response ◽  
Direct Acting Antiviral ◽  
Antiviral Therapies ◽  
Safety Net Hospital ◽  
Direct Acting

Hepatitis C “true” late relapse beyond 48 weeks of sustained virologic response after direct acting antiviral therapy

2017 ◽  
Vol 66 (4) ◽  
pp. 862-863 ◽  
Author(s):  
Thomas Klag ◽  
Julia Dietz ◽  
Christoph R. Werner ◽  
Julia M. Schwarz ◽  
Ulrich M. Lauer ◽  
...  
Keyword(s):  
Hepatitis C ◽  
Antiviral Therapy ◽  
Sustained Virologic Response ◽  
Virologic Response ◽  
Late Relapse ◽  
Direct Acting Antiviral ◽  
Direct Acting
Sign in / Sign up

Export Citation Format

Share Document